bioMerieux' profits up 18% thanks to international sales
This article was originally published in Clinica
Profits at French diagnostics company bioMerieux rose 18% in 1995 compared with the year before to Fr 139 million ($27.8 million). Sales volume increased 6% over the year, but weakness in the US dollar and several European currencies meant revenues rose just 2.1% to Fr 2,461 million in fiscal 1995 in what president Alain Merieux termed a difficult economic environment.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.